Joint Filing Agreement
Exhibit 99.1
In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D dated December 26, 2019, as amended by Amendment No. 1 to Schedule 13D dated October 8, 2020 (including any further amendments thereto) with respect to the shares of Common Stock, $0.001 par value per share, of Five Prime Therapeutics, Inc., a Delaware corporation. This Joint Filing Agreement shall be filed as an Exhibit to such Statement.
Dated: October 8, 2020
| BIOTECHNOLOGY VALUE FUND, L.P. | BIOTECHNOLOGY VALUE TRADING FUND OS LP | |||
| By: | BVF I GP LLC., its general partner | By: | BVF Partners L.P., its investment manager | |
| By: | BVF Inc., its general partner | |||
| By: |
/s/ Xxxx X. Xxxxxxx |
|||
| Xxxx X. Xxxxxxx | By: | /s/ Xxxx X. Xxxxxxx | ||
| Chief Executive Officer | Xxxx X. Xxxxxxx | |||
| President | ||||
| BVF I GP LLC | ||||
| BVF GP HOLDINGS LLC | ||||
| By: | /s/ Xxxx X. Xxxxxxx | |||
| Xxxx X. Xxxxxxx | By: | /s/ Xxxx X. Xxxxxxx | ||
| Chief Executive Officer | Xxxx X. Xxxxxxx | |||
| Chief Executive Officer | ||||
| BIOTECHNOLOGY VALUE FUND II, L.P. | ||||
| BVF PARTNERS L.P. | ||||
| By: | BVF II GP LLC, its general partner | |||
| By: | BVF Inc., its general partner | |||
| By: |
/s/ Xxxx X. Xxxxxxx |
|||
| Xxxx X. Xxxxxxx | By: | /s/ Xxxx X. Xxxxxxx | ||
| Chief Executive Officer | Xxxx X. Xxxxxxx | |||
| President | ||||
| BVF II GP LLC | ||||
| BVF INC. | ||||
| By: | /s/ Xxxx X. Xxxxxxx | |||
| Xxxx X. Xxxxxxx | By: | /s/ Xxxx X. Xxxxxxx | ||
| Chief Executive Officer | Xxxx X. Xxxxxxx | |||
| President | ||||
| BVF PARTNERS OS LTD. | ||||
| /s/ Xxxx X. Xxxxxxx | ||||
| By: | BVF Partners L.P., its sole member | XXXX X. XXXXXXX | ||
| By: | BVF Inc., its general partner | |||
| By: |
/s/ Xxxx X. Xxxxxxx |
|||
| Xxxx X. Xxxxxxx | ||||
| President | ||||
